Black Rock Inc. Athenex, Inc. Transaction History

Black Rock Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.12 - $0.21 $120,557 - $210,975	-1,004,647 Reduced 42.96%	1,333,665 $200,000
Q3 2022 Nov 14, 2022	BUY	$0.24 - $1.11 $55,574 - $257,030	231,559 Added 10.99%	2,338,312 $629,000
Q2 2022 Aug 12, 2022	SELL	$0.41 - $0.91 $1.79 Million - $3.97 Million	-4,366,345 Reduced 67.45%	2,106,753 $863,000
Q1 2022 May 12, 2022	SELL	$0.79 - $1.59 $403,595 - $812,300	-510,881 Reduced 7.32%	6,473,098 $5.37 Million
Q4 2021 Feb 10, 2022	BUY	$1.36 - $2.94 $60,639 - $131,088	44,588 Added 0.64%	6,983,979 $9.5 Million
Q3 2021 Nov 09, 2021	BUY	$2.97 - $4.84 $605,951 - $987,476	204,024 Added 3.03%	6,939,391 $20.9 Million
Q2 2021 Aug 11, 2021	BUY	$3.71 - $5.13 $25 Million - $34.6 Million	6,735,367 New	6,735,367 $31.1 Million

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.